CN111097040A - Antiviral lung-heat clearing peptide - Google Patents
Antiviral lung-heat clearing peptide Download PDFInfo
- Publication number
- CN111097040A CN111097040A CN202010101795.0A CN202010101795A CN111097040A CN 111097040 A CN111097040 A CN 111097040A CN 202010101795 A CN202010101795 A CN 202010101795A CN 111097040 A CN111097040 A CN 111097040A
- Authority
- CN
- China
- Prior art keywords
- extract
- lung
- coronavirus
- effect
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 14
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 38
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 9
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 9
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 9
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 9
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 9
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 28
- 235000012754 curcumin Nutrition 0.000 claims description 14
- 229940109262 curcumin Drugs 0.000 claims description 14
- 239000004148 curcumin Substances 0.000 claims description 14
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 70
- 241000700605 Viruses Species 0.000 abstract description 39
- 241000712461 unidentified influenza virus Species 0.000 abstract description 29
- 241000711573 Coronaviridae Species 0.000 abstract description 27
- 230000002401 inhibitory effect Effects 0.000 abstract description 22
- 210000004072 lung Anatomy 0.000 abstract description 22
- 230000002708 enhancing effect Effects 0.000 abstract description 21
- 238000002474 experimental method Methods 0.000 abstract description 18
- 208000015181 infectious disease Diseases 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 13
- 244000052769 pathogen Species 0.000 abstract description 13
- 206010037660 Pyrexia Diseases 0.000 abstract description 12
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 10
- 206010011224 Cough Diseases 0.000 abstract description 10
- 244000194101 Ginkgo biloba Species 0.000 abstract description 10
- 235000008100 Ginkgo biloba Nutrition 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 235000011201 Ginkgo Nutrition 0.000 abstract description 9
- 206010035737 Pneumonia viral Diseases 0.000 abstract description 9
- 208000009421 viral pneumonia Diseases 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 8
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 7
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract description 7
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 230000002147 killing effect Effects 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 230000010076 replication Effects 0.000 abstract description 5
- 206010047470 viral myocarditis Diseases 0.000 abstract description 5
- 235000020694 echinacea extract Nutrition 0.000 abstract description 4
- 102000053602 DNA Human genes 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 abstract description 3
- 238000012606 in vitro cell culture Methods 0.000 abstract description 3
- 241000266851 Hedysarum polybotrys Species 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 235000014134 echinacea Nutrition 0.000 description 54
- 240000004530 Echinacea purpurea Species 0.000 description 37
- 238000011160 research Methods 0.000 description 22
- 244000133098 Echinacea angustifolia Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000011282 treatment Methods 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 14
- 206010035664 Pneumonia Diseases 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000036737 immune function Effects 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000000144 pharmacologic effect Effects 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 101800004361 Lactoferricin-B Proteins 0.000 description 10
- 208000009525 Myocarditis Diseases 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000009429 Ginkgo biloba extract Substances 0.000 description 8
- 244000042430 Rhodiola rosea Species 0.000 description 8
- 235000003713 Rhodiola rosea Nutrition 0.000 description 8
- 229940068052 ginkgo biloba extract Drugs 0.000 description 8
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000002155 anti-virotic effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229940045811 echinacea purpurea extract Drugs 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- 241000997135 Rhodiola crenulata Species 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 206010069351 acute lung injury Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- -1 isobutyric acid amine Chemical class 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 3
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 2
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000219050 Polygonaceae Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000000312 effect on influenza Effects 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 235000004330 tyrosol Nutrition 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- NWBWCXBPKTTZNQ-UHFFFAOYSA-N (16S)-4-(N-Acetyl-anthraniloyloxy)-20-aethyl-1alpha,14alpha,16-trimethoxy-aconitan-8,9-diol Natural products C1CC(OC)C2(C3C4)C5CC(C(C6)OC)C(OC)C5(O)C6(O)C4C2N(CC)CC31OC(=O)C1=CC=CC=C1NC(C)=O NWBWCXBPKTTZNQ-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 101710163504 Phaseolin Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N alpha-isobutyric acid Natural products CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 description 1
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- NWBWCXBPKTTZNQ-QOQRDJBUSA-N y4m5974f7z Chemical compound O([C@]12CN([C@@H]3[C@H]4[C@]5(O)[C@@]6(O)[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1C4)[C@@H](OC)CC2)CC)C(=O)C1=CC=CC=C1N=C(C)O NWBWCXBPKTTZNQ-QOQRDJBUSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The antiviral lung-heat clearing peptide is characterized in that raw hedysarum polybotrys extract, large flower extract, echinacea extract, cassia twig extract, giant knotweed rhizome extract, tetrahydrocurcumin, ginkgo extract, lactoferrin peptide and auxiliary materials are used as raw materials. The product has effects in enhancing immunity, clearing lung-heat, removing toxic substances, preventing infection of coronavirus and influenza virus, preventing and treating viral pneumonia and myocarditis, resisting pathogen, killing bacteria, relieving inflammation, nourishing lung, protecting lung, preventing fever, relieving cough, eliminating phlegm, and enhancing immunity. Experiments prove that the product can inhibit the replication of coronavirus and avian influenza virus and prevent and treat viral pneumonia in vitro cell culture, can inhibit the coronavirus and avian influenza virus in mouse experiments, and has good inhibitory effect on deoxyribonucleic acid of the viruses.
Description
The technical field is as follows: the present invention belongs to a special medical food combining Chinese traditional medicine and western medicine, particularly to a special medical food which is processed by natural pollution-free high-quality plant extracts and other raw materials by the modern most advanced ultrasonic extraction technology.
Secondly, background art: the product has effects in enhancing immunity, resisting virus and various influenza virus infections, preventing and treating viral pneumonia and myocarditis, resisting pathogen, killing bacteria, relieving inflammation, nourishing and protecting lung, clearing lung-heat, removing toxic substances, and preventing and clearing away heat. The product is a hard capsule prepared from natural medicinal and edible plants and biological products serving as raw materials, and has the advantages of high purity, strong biological activity, good absorption and utilization, no toxic or side effect, convenient taking and obvious effect.
Thirdly, the invention content: the life is loved, and the coronavirus infection is scientifically prevented and treated. The national Weijian Commission soon reminds people in China, and the coronavirus pandemic is particularly important to be prevented. Coronavirus possesses a surprising infectivity, and a viral droplet inhaled directly into the air is infected. The severe epidemic of sars in 2003 has made people aware of the fear of viral infections. Viral disease infection has become a pandemic disease that human society must address. Therefore, the product is innovated and researched, has important and profound social significance and economic benefit, and can also benefit mankind.
Fourthly, raw material formula: 50-100 kg of raw radix hedysari extract, 40-90 kg of rhodiola crenulata extract, 30-80 kg of echinacea extract, 20-70 kg of cassia twig extract, 10-60 kg of polygonum cuspidatum extract, 15-65 kg of tetrahydrocurcumin, 25-45 kg of ginkgo extract, 5-50 kg of lactoferrin peptide and auxiliary materials as raw materials.
Fifthly, the technical scheme is as follows:
radix Hedysari extract (Radix Hedysari extract) is prepared from Radix Hedysari, which is dried root of multiple-sequence Radix Hedysari of Leguminosae. It is warm in nature, sweet in flavor and enters lung and spleen meridians. Has effects in strengthening body resistance, consolidating constitution, invigorating lung, invigorating yang, consolidating superficial resistance, arresting sweating, clearing away heat and toxic materials, preventing and treating toxic pneumonia, promoting granulation, inducing diuresis, relieving swelling, healing sore, and promoting granulation. It is suitable for pneumonia caused by various viruses such as lung qi debilitation, lung deficiency short breath, viral pneumonia, coronavirus and avian influenza. Modern medical research shows that the traditional Chinese medicine has a plurality of functions of enhancing immune function, resisting pathogens, resisting viruses, preventing warm, resisting inflammation, preventing and treating pneumonia and myocarditis caused by viruses, preventing and treating respiratory virus infection and the like.
The chemical components of radix hedysari comprise radix hedysari glycoside, isoacyl radix hedysari glycoside, isohedysari glycoside, kaempferol, quercetin, radix hedysari polysaccharide, stearic acid, ferulic acid, β -sitosterol, choline, various trace elements and the like.
The pharmacological action is as follows: 1. the in vivo test shows that the radix hedysari extract has the functions of reducing death, prolonging survival period, protecting mice from myocarditis or lightening myocarditis pathological changes for the coronavirus infected mice. Including coronavirus, HIV, etc. Meanwhile, the radix hedysari extract can also inhibit cytopathic effect after virus infection, and has growth inhibition effect on replicating viruses.
2. And (3) resisting pathogens: radix hedysari has obvious inhibition effect on diplococcus pneumoniae, staphylococcus aureus, bacillus anthracis, corynebacterium diphtheriae, staphylococcus albus, streptococcus hemolyticus and the like in vitro.
3. Anti-inflammatory: the radix hedysari extract has good prevention and treatment effects on pneumonia caused by coronavirus, including pneumonia caused by various viruses such as influenza virus, avian influenza and the like. Animal experiments prove that the radix hedysari extract can obviously inhibit the process of pneumonia infected by the viruses when being injected into rats.
4. Enhancing the immune function: the latest clinical research proves that the radix hedysari extract, the polysaccharide and other components can obviously improve the nonspecific immune function. Has the functions of promoting and enhancing humoral and cellular immunity, obviously activating interferon environment, inducing self, promoting the generation of interferon, promoting the activity volatilization and the like.
5. Preventing and treating viral myocarditis: clinical application proves that the radix hedysari extract has good effect on treating myocarditis. Myocarditis is commonly caused by exogenous infection, upper respiratory tract infection, and 1-5 weeks after infection with viruses such as coronavirus. The latest research shows that the effective components of radix hedysari have the functions of resisting virus and regulating immunity, have the activation effect on interferon, and have the effects of improving the growth of endothelial cells and enhancing the myocardial contraction. Viral serological diagnosis of myocarditis is related to coronavirus, and radix Hedysari extract has protective effect on myocarditis infected by coronavirus and other viruses, and can improve cardiac function of patients, and has good effect of preventing and treating myocarditis.
In addition, radix Hedysari extract also has effect of resisting pulmonary hypertension.
The Rhodiola crenulata extract (Rhodiola Rosea) is a whole herb of Rhodiola crenulata of Crassulaceae, and is cold in nature, sweet in taste, astringent and capable of entering spleen and lung channels. Has effects in strengthening body resistance, consolidating constitution, invigorating qi, nourishing blood, clearing away heat, relieving fever, clearing away lung heat, relieving cough, promoting blood circulation, and dispelling blood stasis. Can be used for treating pneumonia, fever, coronary heart disease, viral myocarditis, pulmonary edema, chronic pulmonary obstruction, anoxia, and fatigue.
The chemical components of rhodiola root contain salidroside, flavonoid, cinnamyl alcohol, β -sitosterol, gallic acid, carrot, 19 amino acids, fatty acid, various mineral substances and trace elements.
The pharmacological action is as follows: 1. and (3) antivirus: the rhodiola rosea extract can effectively prevent coronaviruses, subtype influenza viruses and the like from being adsorbed on host cells, and has extremely strong inhibition effect on the replication process of the viruses in the host cells. The cultured coronavirus attacks of the rhodiola crenulata contain tyrosol which has a good anti-attack effect. The mechanism is that rhodiola rosea tyrosol and virus compete for certain receptor sites on cell membranes simultaneously, thereby blocking the adsorption and penetration processes of the virus.
2. Anti-inflammatory: animal experiments show that the rhodiola rosea decoction has obvious inhibition effect on various pneumonia of rats caused by virus after being infused, can inhibit virus inflammation exudation, and can prevent leukocytosis caused by subcutaneous injection.
3. Enhancing the immune function: animal experiments prove that the rhodiola rosea extract can promote the phagocytic function of a reticuloendothelial system of a mouse and increase a specific antibody of the serum of the mouse. The rhodiola rosea saponin can also promote T, B lymphoreaction stimulated by lymphoblastoid, has a promoting effect on the immunologic function of the spleen of a rat, can enhance the enhancement reaction of splenic T cells on the phaseolin A, promotes the induction of interleukin-2, and improves the activity of spleen natural killer cells. Has good immunity enhancing effect.
4. Prevention and treatment of viral-induced myocarditis: research shows that the rhodiola rosea polysaccharide can obviously inhibit the release of myocardial enzyme caused by virus infection of in vitro cultured myocardial cells and obviously reduce the proliferation amount of the virus in the myocardial cells, and research results of a mouse model of Coxsackie B6 virus induced by influenza show that the rhodiola rosea polysaccharide has obvious promotion effect on the improvement of myocardial function of a sick mouse, enhances the antiviral ability of the mouse and has certain prevention and treatment effect on viral-infected myocarditis. In addition, radix Rhodiolae has antitoxin, antifatigue, and anoxia resisting effects.
(III), Echinacea purpurea extract (Echinacea extract), also known as Echinacea purpurea, an perennial herb Echinacea purpurea of Echinacea, is a wild flower of Compositae, belonging to perennial herb Echinacea purpurea. Antibacterial, antifungal, antiinflammatory, antiviral, free radical scavenging, and antitumor effects. The composition is clinically applied to treating cold, bronchial asthma, acute virus infection, upper respiratory tract infection, cancer and immune diseases.
Chemical components: echinacea purpurea mainly contains sugar, caffeic acid derivatives, polyacetylene and isobutyric acid amine. Volatile oil, flavone, alkaloid, phytosterol raw sugar, unsaturated ketone, vitamin A, vitamin C, vitamin E, mineral potassium, calcium, iodine, sulfur, magnesium, iron, zinc and the like.
The pharmacological action is as follows: 1. and (3) antibiosis: in vitro tests of Echinacea purpurea prove that the Echinacea purpurea has inhibitory activity on staphylococcus aureus and streptococcus pyogenes; the multi-block components have strong inhibitory activity on pseudomonas aeruginosa and escherichia coli; the Echinacea purpurea extract has effect in inhibiting Mycobacterium tuberculosis, and can inhibit the growth of epidermal fresh bacteria.
The echinacea purpurea extract has different degrees of inhibition effects on clinically separated staphylococcus aureus, group B streptococcus, klebsiella, influenza bacillus and epidermic coccus. Has strong inhibiting effect on staphylococcus aureus, group B streptococcus and staphylococcus epidermidis.
Animal experiments show that the echinacea purpurea can reduce the animal mortality rate caused by staphylococcus aureus infection, and the echinacea purpurea has a certain protection effect on staphylococcus aureus infected animals. Echinacea extract was found to stop streptococcal infections in rats. The echinacea purpurea can effectively inhibit infection diffusion in bodies of experimental animals, the effect is related to an action mechanism for inhibiting hyaluronidase, the hyaluronic acid protects cells from microbial invasion, tissues are not easy to be infected and reproduced by microbes, and the hyaluronidase plays a role in decomposing the hyaluronic acid.
2. Antifungal activity: echinacea purpurea polysaccharide has antifungal effect. The echinacea polysaccharide is used for treating the immunodeficient mouse model, so that the candida albicans infection in the kidney of the mouse can be obviously reduced, and the candida infection with lethal dose can be obviously protected. The test shows that the echinacea purpurea can enhance the capability of immune cells of mice to inhibit candida albicans. Monocytes of healthy humans have increased phagocytic capacity against Candida albicans after treatment with Echinacea purpurea extract.
3. And (3) antivirus: the echinacea purpurea extract has obvious inhibition effect on influenza virus, herpes virus and poliomyelitis virus; the Echinacea purpurea extract has inhibitory activity against influenza Virus A2, and also inhibits replication of encephalomyocarditis Virus (EMC-Virus) and filterable stomatitis Virus (VSV). Echinacea purpurea polysaccharide is the main antiviral component, and has 80% inhibition effect on herpes simplex virus replication.
It is reported that: the results of the internal anti-virus tests of the echinacea purpurea carried out by researchers of domestic medical colleges show that the echinacea purpurea has obvious inhibition effect on influenza virus and has certain effect on the Asahi group viruses COXB3 and COXB5, the respiratory syncytial virus RSV and the herpes virus HSV-2. For the mouse pneumonia caused by the influenza virus, the echinacea purpurea is administrated by gastric gavage continuously for 5 days, the lung inflammation can be obviously reduced, the lung index is obviously reduced compared with that of a control group, and the echinacea purpurea has an obvious inhibiting effect on the mouse pneumonia caused by the influenza virus.
4. Resisting infection: in vivo and in vitro pharmacological experimental studies, echinacea and the components contained in the echinacea seem to have only mild antibacterial activity. Surprisingly, however, a variety of echinacea containing products have shown clinically robust broad spectrum anti-infective effects. Obviously, the anti-infection effect of echinacea purpurea is not a simple effect of killing and inhibiting pathogen, but a deeper mechanism.
The research of foreign medical experts finds that the powerful anti-infection function of echinacea purpurea not only directly inhibits pathogens, but also improves the autoimmunity of human body to exert the effect by stimulating the immune system of the organism. The main action mechanism treatment of the echinacea purpurea for effectively resisting infection is as follows: (1) and stimulating macrophage activity. (2) Increasing phagocytic activity of the cells. (3) Stimulation of T-cell proliferation. (4) And promoting the production of interferon cytokines.
5. Anti-inflammatory action: inflammatory response is the normal defense and relief response of body tissues to various infections and non-infectious injuries, and is the main pathological change of many diseases.
Pharmacological experiments and clinical researches show that echinacea has extremely strong anti-inflammatory activity, and the anti-inflammatory activity of echinacea is derived from the activity of inhibiting hyaluronidase, stimulating adrenal cortex, inhibiting inflammatory factor cyclooxygenase, 5-lipoxygenase and arachidonic acid.
6. Enhancing the immune function: a series of pharmacological and clinical researches show that the echinacea purpurea has wide anti-infection capacity because the echinacea purpurea can obviously improve the immunity of human bodies. Therefore, the composition has high effect on treating various infectious diseases. Echinacea is now a famous immunoregulatory herbal medicine in western countries. Because the echinacea purpurea is most effective in treating cold, influenza and various infectious diseases of the whole body, the echinacea purpurea has the function of promoting the immune system of the human body. As a result of tens of intensive and thorough research, echinacea purpurea has the effect of regulating the human immune system, mainly by means of systemic macrophages and other effector cells, improving the alertness and vitality of the human monitoring system, especially the mucosal immune system, and fighting invading pathogens. It has also been reported that echinacea can promote phagocytic function and promote activity of monocytes, macrophages and NK cells. Has effects of preventing influenza and shortening common cold period.
7. Antioxidation: more and more experiments have confirmed that many common diseases are associated with antioxidant substances in humans, such as: respiratory tract infection, periodontal disease, rheumatoid arthritis, cardiovascular disease, cancer, and dermatoses. The use of antioxidant can inactivate oxygen free radicals and treat related diseases.
The polyphenol components such as echinacoside, chicoric acid, caffeic acid, etc. in Echinacea purpurea have free radical scavenging effect, can protect skin protoprotein III from damage of free radical degradation, and can be used for preventing and treating light skin injury.
8. The medicine has special effects of treating cold: echinacea purpurea has the widest treatment application and the best curative effect, and the most studied is the treatment of upper respiratory fluid infection, including cold, influenza, tonsillitis, bronchitis and cough; the curative effect for treating cold and flu is particularly remarkable.
Echinacea purpurea relies on multiple mechanisms of action to exert anti-cold and anti-influenza effects. Echinacea purpurea plays a role in activating immune system, inducing interferon, preventing virus replication, protecting cell membrane, blocking virus invasion to mucosal endothelial cells, resisting inflammation, resisting allergic reaction and other biological effects, and can resist cold and influenza virus invasion together, so that the treatment effect is very obvious, and the early use effect is excellent. The echinacea purpurea has different cold resisting mode from traditional Chinese medicine, can simultaneously play the roles of resisting virus and improving immunity, has the double effects of relieving exterior syndrome and supplementing agent, and can treat both principal and secondary aspects of diseases. Therefore, the echinacea purpurea can be used at any stage of cold, and has better effect particularly at the initial stage of cold, and when you feel the first symptom of cold, the echinacea purpurea preparation can be taken immediately to stop the cold quickly or relieve the symptom, shorten the course of disease and enhance the disease resistance of patients.
In addition, the echinacea purpurea can also effectively relieve symptoms, shorten the course of disease, treat both symptoms and root causes, and prevent cold and influenza.
9. Treating sphagitis: the sphagitis belongs to the effective treatment field of echinacea purpurea. A plurality of random double-blind placebo control experiments prove that echinacea has the relieving effect on various sphagitis and has better effect on viral infection. The inhibition of treatment with the purple cone is good. Treatment with Echinacea can inhibit infection and various symptoms and accelerate recovery. For some serious infections, echinacea purpurea is selected as an auxiliary therapeutic agent of antibiotics, and has the effects of shortening the course of disease and relieving symptoms, and clinical research results carried out so far are all full of keken echinacea to have good curative effects on treating sphagitis infection.
10. The medicine is safe and effective for treating the upper respiratory tract infection of children: the echinacea purpurea is safe and effective in treating the upper respiratory tract infection of children including cold, and in the clinical test of treating 209 children with cold of 3-5 years old, the echinacea purpurea can obviously reduce the number of days of fever of the children when being ill, compared with a control group, and other control clinical tests also prove that the echinacea purpurea is effective in the cold and the flu of the children.
As a result of comparative study on 1280 children suffering from bronchitis by echinacea, the german medical scientist found that treatment with echinacea can significantly shorten the course of disease and accelerate disease healing compared with other treatments, and even is better than single use of antibiotics, because bronchitis is mostly caused by viral infection, the single use of antibiotics has poor curative effect, and echinacea can play double roles of promoting immunologic function and resisting virus. Research shows that the patients with 'pulmonary dry cough' or obstructive tracheitis are improved most obviously, and the combined treatment effect of antibiotics and echinacea is better.
(IV) ramulus Cinnamomi extract (astor Bean), ramulus Cinnamomi is the twig of Cinnamomum cassia Presl of Lauraceae. Warm in nature, pungent and sweet in flavor. It enters bladder, heart and lung meridians. Has the effects of clearing away heat and toxic materials, dispelling cold, relieving exterior syndrome, warming channels, activating yang, etc. Can be used for relieving exterior syndrome due to sweating, common cold, fever, and phlegm retention in chest and spleen. Modern medical research shows that the cassia twig extract has the functions of clearing away heat and toxic material, resisting virus, resisting bacteria and diminishing inflammation, enhancing immunity, relieving fever, eliminating phlegm and stopping cough, protecting cardiac muscle, tranquilizing and relieving pain and the like.
The chemical components of ramulus Cinnamomi include cinnamyl alcohol, coumarin, β -sitosterol, protocatechuic acid, and glucose.
The pharmacological action is as follows: 1. and (3) resisting pathogens: the ethanol extract has certain inhibitory effect on Staphylococcus aureus, Diplococcus pneumoniae, Escherichia coli, Bacillus proteus, Bacillus dysenteriae and Bacillus typhi.
2. And (3) antivirus: clinical research proves that the cassia twig decoction has an inhibiting effect on 6-1 strains of Asia and A influenza viruses and coronavirus, and the cassia twig alcohol extract on embryos has a remarkable inhibiting effect on pneumonia viruses and influenza viruses by using human embryo pronephrosis single-layer epithelial tissue culture. In addition, the cassia twig extract is also used for treating cold and fever clinically.
3. And (3) clearing heat and cooling: the cassia twig decoction is injected into abdominal cavity at 125mg/kg and 250mg/kg and is infused into stomach at 500mg/kg, and has the function of cooling fever of mice and rabbits caused by normal body temperature, typhoid fever and paratyphoid fever of the mice. It also has antipyretic effect on fever caused by influenza.
4. Anti-inflammatory: the ramulus Cinnamomi volatile oil is discharged from respiratory tract, and has effects of eliminating inflammation, relieving inflammation of respiratory tract, and increasing leukocyte by using cinnamyl alcohol.
5. Improving immunity: the cassia twig extract shows the effect of inhibiting complement activity on heterophily antibody reaction and has good function of enhancing immunity.
And (V) extract of rhizoma Polygoni Cuspidati (Japanese Polygonaceae) which is root and stem of Polygonum cuspidatum of Polygonaceae. It is cold in nature, bitter in taste, entering liver, gallbladder and lung meridians. Has effects in clearing away heat and toxic materials, removing dampness, eliminating jaundice, dispelling blood stasis, relieving pain, relieving cough, eliminating phlegm, and removing toxic materials. Is suitable for treating epidemic febrile disease, cough due to lung heat, arthralgia and myalgia, venomous snake bite, etc. Modern researches have considered that giant knotweed has the effects of resisting bacteria and coronavirus, preventing heat and clearing heat, protecting heart and the like.
Chemical components: contains nutrient components such as emodin, lappaconitine, chrysophanol, resveratrol glucose, resveratrol, etc.
The pharmacological action is as follows: 1. and (3) resisting pathogens: the latest clinical research shows that the giant knotweed extract has good bacteriostatic action. Has different degrees of inhibiting effects on staphylococcus aureus, streptococcus pneumoniae, diplococcus hepaticus, staphylococcus pneumoniae white staphylococcus, paratyphoid bacillus and the like. The antibacterial mechanism is to inhibit the synthesis of nucleic acid and protein of bacterial cells and the sugar metabolism of the bacterial cells.
2. And (3) antivirus: the giant knotweed extract has good inhibition effect on 7 viruses such as coronavirus herpes simplex virus, influenza virus, Asian influenza A Jing strain 68-1 virus and the like. Meanwhile, the giant knotweed rhizome emodin has obvious antiviral effect on mice infected by the herpes simplex virus, the influenza virus and the coronavirus.
3. And (3) clearing heat: when the giant knotweed rhizome decoction is infused into the rabbits with fever caused by pneumococcus infection, the body temperature of the rabbits with pathological fever is reduced, and the content of PGE in the third ventricular flow is obviously reduced. One of the cooling mechanisms is by affecting the level of the central loop nucleotide.
(hexa) tetrahydrocurcumin (clrymins) curcumin is a polyphenolic compound present in turmeric. Recent medical research shows that curcumin has wide pharmacological activity.
The pharmacological action is as follows: 1. antifungal action: in the latest clinical research, curcumin has obvious inhibiting and killing effects on pneumococcus, helicobacter pylori, streptococcus pneumoniae, typhoid bacillus, staphylococcus aureus and other germs. An animal experiment shows that the effective rate of curcumin for inhibiting mouse pneumococcus is 98.1%, and the curcumin has better effect on mice infected with the curcumin and drunk by decoction.
2. Enhancing the immune function: animal experiments show that curcumin can promote rat lymphocyte mitosis, increase the number of splenic lymphocytes of a mouse, stimulate a reticuloendothelial cell system and has a good immune promotion effect.
3. And (3) antivirus: recent research shows that curcumin is a broad-spectrum antiviral agent, is an inhibitor for preventing coronavirus, influenza virus and avian influenza virus from infecting cells, and can also prevent the coronavirus, the influenza virus and the avian influenza virus from replicating in the cells. Coronavirus, influenza virus and avian influenza virus are viruses which cause fever acutely and cause serious harm to human life. Studies have demonstrated that curcumin interferes with and prevents the response of cells to infection. Curcumin can inhibit the replication of the viruses in-vitro cell cultures, can effectively inhibit coronavirus, influenza virus and avian influenza virus in mouse experiments, and has good inhibitory effect on deoxyribonucleic acid of the viruses.
4. Anti-inflammatory: animal experiments prove that curcumin has extremely strong anti-inflammatory effect on acute, subacute and chronic inflammation of mice and rats. The latest research considers that curcumin has obvious anti-inflammatory effect on various inflammations caused by various viruses, and particularly has better effect on acute and subacute pneumonia.
(VII) Ginkgo biloba extract (Semen Ginkgo) is dry mature seed of Ginkgo biloba of Ginkgoaceae. Neutral in nature, sweet in flavor, bitter and astringent, entering lung meridian. Has effects in astringing lung, relieving asthma, promoting blood circulation, relieving cough, eliminating phlegm, and relieving pain. The ginkgo biloba extract is used for treating lung deficiency cough and asthma, bronchial asthma, viral pneumonia and other symptoms, and has the functions of enhancing immunity, resisting bacteria, resisting virus, resisting viral pneumonia, reducing cholesterol, eliminating free radicals, enhancing coronary blood flow and the like according to modern medical research.
Chemical components: ginkgo mainly contains active ingredients such as flavonoid compounds, bilobalide, ginkgolide, terpene lactone compounds, various trace elements and the like.
The pharmacological action is as follows: 1. enhancing the immune function: animal experiments prove that the ginkgo biloba extract can promote the proliferation reaction of splenic T lymphocytes and B lymphocytes of tumor-bearing mice respectively induced by concanavalin and LPS no matter the ginkgo biloba extract is cultured in vitro or administered in vivo, and the ginkgo biloba extract has obvious regulating effect on low cellular immunity and humoral immunity of the tumor-bearing mice.
2. And (3) antibiosis: the ginkgo biloba extract has strong antibacterial effect on human tubercle bacillus, pneumococcus, staphylococcus aureus and the like in vitro tests.
3. And (3) antivirus: research shows that the ginkgo extract has a good inhibitory effect on viruses, and the ginkgo can enhance the antiviral reaction of organisms. The experimental results show that the mortality rate related to the viral pneumonia of the mice treated by the ginkgetin is obviously reduced compared with the control group. Meanwhile, the lung injury of mice treated with ginkgetin is far less than that of the control group during virus infection. The action mechanism is to protect the lung tissue by enhancing the immune response of the organism. Therefore, the ginkgo biloba extract can play an antiviral role.
4. Preventing and treating acute lung injury: through establishing an acute lung injury animal model experiment, the influence of the ginkgo extract on the morphology and the biology of lung tissues is observed, and the heart rate, respiration, frequency, blood gas analysis and related cytokine expression dynamic change results are simultaneously researched, so that the ginkgo extract can inhibit the increase of the content of TNF-a in plasma, relieve the infiltration of interstitial lung inflammatory cells, activate the activity of anti-inflammatory factors in the lung, relieve the edema degree of the lung tissues and play an effective role in protecting the acute lung injury. Therefore, the ginkgo biloba extract has obvious protective effect on acute lung injury.
(VIII) lactoferricin lfcin which is a small peptide containing 25-28 amino acids generated after the degradation of lactoferrin in the milk of a cow in the digestive tract of an animal by acid pepsin. Lactoferricin, a glycoprotein that binds iron, is considered as a prototype protein to be a very important inhibitory mechanism against bacterial infections, is rapidly effective after exposure to pathogenic bacteria, and is a good antibiotic substitute. Has antibacterial, anti-pathogen, antiviral, and immunity enhancing effects.
Biological activity function: 1. and (3) resisting pathogen invasion: lactoferricin is the major active component of the mucosal defence system, which prevents attachment of microorganisms to the respiratory epithelium and has antibody activity against viral bacteria and general antigens. Clinical researches prove that the content of the lactoferrin peptide in the respiratory secretion directly influences the resistance effect of the respiratory mucosa to pathogens, and the effects are in positive correlation. Therefore, the lactoferrin peptide anti-biological antibody has the bactericidal, bacteriolytic, phagocytosis-promoting and agglutination effects which are 200 times higher than those of other protein peptides, plays an extremely important role in early defense of organisms, and plays a role in killing pathogens and targeting cells.
2. And (3) antivirus: recent studies have shown that lactoferricin plays an extremely important role in antiviral, specific antibodies. Clinical studies have shown that the application of lactoferricin can block the spread of coronavirus and influenza virus in upper respiratory tract cells and lower respiratory tract infection, thereby preventing these viral infections and preventing viral patients from spreading the virus. In addition, it has been reported that lactoferricin can be used as an effective agent for the emergency prevention and treatment of viruses, and it can neutralize the entry of viruses into the viral region and thus prevent the viruses from adsorbing and invading cells. Animal experiments show that the lactoferrin peptide can be used for emergency prevention of mouse influenza, and the specific immunity protection rate of highly pathogenic coronavirus and avian influenza virus reaches 81%. Thus, it was demonstrated that lactoferricin has a significant antiviral effect.
3. Enhancing the immune function: clinical studies have shown that oral administration of lactoferricin results in the release of neutrophils, when lactoferricin is present on the surface of various immunocytes, such as lymphocytes, due to the activity of Natural Killer (NK) cells in spleen cells. Under the condition of general infection, the yield of the neutrophils induced by the lactoferricin is 6 times of that of the neutrophils in normal times, the release amount is increased by 20 times, and the effects of remarkably promoting the phagocytosis of the neutrophils and phagocytes, promoting the activity of natural killer cells and promoting the proliferation and regulation of the lymphocytes neutrophils in vivo or in vitro are proved.
In conclusion, the product has the effects of enhancing the immune function, clearing away the lung-heat and detoxifying, preventing various virus infections such as coronavirus, influenza virus and the like, preventing and treating viral pneumonia and myocarditis, resisting pathogens, sterilizing and diminishing inflammation, nourishing and protecting the lung, preventing warm and clearing away heat, relieving cough and reducing sputum, enhancing the immune function and the like. Experiments prove that the product can inhibit the replication of coronavirus and avian influenza virus and prevent and treat viral pneumonia in vitro cell culture, can inhibit the coronavirus and avian influenza virus in mouse experiments, and has good inhibitory effect on deoxyribonucleic acid of the viruses.
Sixth, the embodiment:
example (b): taking 50-100 kg of raw hedysarum polybotrys, 40-90 kg of rhodiola crenulata, 30-80 kg of echinacea, 20-70 kg of cassia twig, 10-60 kg of giant knotweed rhizome, 15-65 kg of tetrahydrocurcumin, 25-45 kg of ginkgo, 25-45 kg of lactoferrin peptide and auxiliary materials as raw materials, respectively crushing the raw materials into 50 meshes, respectively taking 70% ethanol as an extraction solvent, respectively, carrying out suction filtration and 2-time ultrasonic extraction on filter residues by using a vacuum pump after ultrasonic treatment is finished, combining filtrates obtained in two times, concentrating by using a rotary evaporator, feeding concentrated solution into an evaporator for vacuum drying to obtain various raw material extracts, then mixing the raw material extracts with the residual curcumin and the lactoferrin peptide in the formula, uniformly stirring, feeding into a filling machine, filling the raw materials into capsules, and (5) inspecting and packaging to obtain a finished product.
Claims (1)
1. The preparation process of the antiviral lung-heat clearing peptide is characterized by comprising the following steps: respectively crushing the raw materials into 50 meshes, respectively taking 70% ethanol as an extraction solvent, carrying out suction filtration by using a vacuum pump after ultrasonic treatment at 40 ℃ for 40min, carrying out ultrasonic extraction on filter residues for 2 times after ultrasonic treatment is finished, combining filtrates obtained in two times, concentrating by using a rotary evaporator, sending the concentrated solution into an evaporator for vacuum drying to obtain various raw material extracts, mixing the raw material extracts with the residual curcumin and lactoferrin peptide in the formula, uniformly stirring, sending into a filling machine, filling the raw materials into capsules, inspecting, and packaging to obtain finished products.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010101795.0A CN111097040A (en) | 2020-02-19 | 2020-02-19 | Antiviral lung-heat clearing peptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010101795.0A CN111097040A (en) | 2020-02-19 | 2020-02-19 | Antiviral lung-heat clearing peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111097040A true CN111097040A (en) | 2020-05-05 |
Family
ID=70428080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010101795.0A Pending CN111097040A (en) | 2020-02-19 | 2020-02-19 | Antiviral lung-heat clearing peptide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111097040A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111789880A (en) * | 2020-05-07 | 2020-10-20 | 郑州航空港百桥生物科技有限公司 | Application of cinnamon extract in inhibiting entry and replication of novel COVID-19 coronavirus into cells |
GB2593452A (en) * | 2020-03-16 | 2021-09-29 | Mead Johnson Nutrition Co | Use of lactoferrin |
IT202000011983A1 (en) * | 2020-05-21 | 2021-11-21 | Neilos S R L | COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES OF THE RESPIRATORY TRACT AND AS A STIMULANT OF THE IMMUNE SYSTEM |
WO2021242850A1 (en) * | 2020-05-28 | 2021-12-02 | The Regents Of The University Of Michigan | Compositions and methods for preventing and treating sars-cov-2 infection |
WO2021237228A3 (en) * | 2020-05-18 | 2021-12-23 | Tesfazion Amanuel | Method and compound for the treatment of covid-19 |
CN115252590A (en) * | 2022-06-14 | 2022-11-01 | 苏彦雷 | Application of monomer compound emodin in resisting novel coronavirus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105707878A (en) * | 2016-04-19 | 2016-06-29 | 北京希康宁生物技术有限责任公司 | Full nutrition formulation food for tumors |
-
2020
- 2020-02-19 CN CN202010101795.0A patent/CN111097040A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105707878A (en) * | 2016-04-19 | 2016-06-29 | 北京希康宁生物技术有限责任公司 | Full nutrition formulation food for tumors |
Non-Patent Citations (4)
Title |
---|
岑国栋等: ""紫锥菊药理作用研究进展"", 《现代药物与临床》 * |
李加慧等: ""抗病毒中药的药性与功效及其关联性文献研究"", 《中医杂志》 * |
杨慧萍等: ""银杏药用成分及药理作用研究进展"", 《动物医学进展》 * |
王强等: ""资源植物红景天研究综述"", 《新疆农业大学学报》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2593452A (en) * | 2020-03-16 | 2021-09-29 | Mead Johnson Nutrition Co | Use of lactoferrin |
CN111789880A (en) * | 2020-05-07 | 2020-10-20 | 郑州航空港百桥生物科技有限公司 | Application of cinnamon extract in inhibiting entry and replication of novel COVID-19 coronavirus into cells |
WO2021237228A3 (en) * | 2020-05-18 | 2021-12-23 | Tesfazion Amanuel | Method and compound for the treatment of covid-19 |
IT202000011983A1 (en) * | 2020-05-21 | 2021-11-21 | Neilos S R L | COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES OF THE RESPIRATORY TRACT AND AS A STIMULANT OF THE IMMUNE SYSTEM |
WO2021234660A1 (en) * | 2020-05-21 | 2021-11-25 | Neilos S.r.l. | Composition for the prevention and the treatment of diseases of the respiratory tract and as a stimulant of the immune system |
WO2021242850A1 (en) * | 2020-05-28 | 2021-12-02 | The Regents Of The University Of Michigan | Compositions and methods for preventing and treating sars-cov-2 infection |
CN115252590A (en) * | 2022-06-14 | 2022-11-01 | 苏彦雷 | Application of monomer compound emodin in resisting novel coronavirus |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111097040A (en) | Antiviral lung-heat clearing peptide | |
CN110772578A (en) | Human body immunity enhancer for preventing and treating cancer and preparation method thereof | |
CN1251732C (en) | Chinese medicine for treating intrapulmonic infection and SARS | |
CN108042727A (en) | A kind of pharmaceutical composition for treating pharyngitis | |
CN1879788A (en) | Virus-clearing capsule | |
CN101856415B (en) | Chinese herbal medicament oral liquid for treating chicken respiratory infectious disease | |
CN104208453A (en) | Traditional Chinese medicine composition for preventing grass carp hemorrhagic disease and preparation method thereof | |
CN107890486A (en) | A kind of Chinese medicine external anti-inflammation formulation and its preparation method and application | |
CN104983968A (en) | Pyretolysis traditional Chinese medicine composition and preparation method | |
CN111760004B (en) | Traditional Chinese medicine granules for preventing and treating livestock and poultry influenza and application thereof | |
CN107362271A (en) | A kind of Chinese medicine composition for treating breathing problem and preparation method thereof | |
CN103861007B (en) | A kind of Chinese herbal compound preparation for the treatment of chicken diarrhea | |
WO2017129060A1 (en) | Medicine used for treating influenza, upper respiratory tract infection, viral pneumonia | |
CN113350429A (en) | Traditional Chinese medicine composition for preventing and treating African swine fever disease and preparation method and application thereof | |
CN105920380A (en) | Repair traditional Chinese medicine used for treating blood cell infected by flaviviridae | |
CN107617018B (en) | Pharmaceutical composition for treating livestock dermatitis herpetiformis and application method thereof | |
CN110664888A (en) | Anti-inflammatory and antibacterial pharmaceutical composition, and preparation method and application thereof | |
CN105168599B (en) | It is a kind of for preventing and treating the pharmaceutical composition and preparation method thereof of animal influenza virus infection | |
CN104606627B (en) | A kind of pharmaceutical composition for treating grice diarrhoea and preparation method thereof | |
CN110227109B (en) | Composition for chronic eczema of pigs and preparation method thereof | |
CN103656267B (en) | A kind of Chinese medicine composition that is used for the treatment of pig blue-ear disease and its preparation method and application | |
AU2020104238A4 (en) | A medicine for treating Newcastle disease, avian influenza and duck plague | |
CN116421671A (en) | Heat-clearing and detoxifying traditional Chinese medicine composition based on five-flavor disinfection drink, preparation and preparation method | |
CN106074824A (en) | Enhancing immunity and the compositions of prophylactic treatment influenza, preparation technology and purposes | |
CN1631389A (en) | Medicine for treating acute and chronic pharyngitis and its preparing process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200505 |